After the diabetes drug Actos was linked to bladder cancer, the drug’s manufacturer reached a $2.4 billion settlement with claimants. Popular radio program Ringler Radio, conducted by the nation’s largest structured settlement company, Ringler Associates, welcomes Beasley Allen principal Frank Woodson to discuss the case and settlement.
Actos (pioglitazone), manufactured by Takeda Pharmaceuticals and distributed by Eli Lilly and Company, has been under FDA review since September 2010. In June 2011, the FDA issued a warning for Actos, while at the same time drug regulators in France and Germany suspended use of the drug after it was linked to an increased risk for the development of bladder cancer. Despite the risk of developing bladder cancer, Takeda raked in nearly $16 billion off of Actos prior to going generic in late 2012.
For more information on Actos and other litigation Beasley Allen is involved with, visit our website at www.BeasleyAllen.com.